![Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment](https://pub.mdpi-res.com/cells/cells-10-00323/article_deploy/html/images/cells-10-00323-g001.png?1612516155)
Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
![Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12948-019-0113-3/MediaObjects/12948_2019_113_Fig1_HTML.png)
Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text
![Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fcc11304/MediaObjects/13054_2012_Article_703_Fig1_HTML.jpg)
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
![Frontiers | Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications Frontiers | Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications](https://www.frontiersin.org/files/Articles/790122/fimmu-12-790122-HTML/image_m/fimmu-12-790122-g001.jpg)
Frontiers | Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
![Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/bb3b76c5-4126-4951-ab23-1ae03c4a6d0f/bcpt_452_f1.gif)
Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
The Risk of Hyperglycaemia with the use of Rituximab in Rheumatoid Arthritis. Results from a Meta-analysis of Randomised Clinica
![Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fncprheum0424/MediaObjects/41584_2007_Article_BFncprheum0424_Fig1_HTML.jpg)
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
![Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis - Medical Pharmacology and Therapeutics, 4e Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis - Medical Pharmacology and Therapeutics, 4e](https://doctorlib.info/pharmacology/medical-pharmacology-therapeutics/medical-pharmacology-therapeutics.files/image257.jpg)
Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis - Medical Pharmacology and Therapeutics, 4e
![Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-017-0612-x/MediaObjects/12325_2017_612_Fig1_HTML.gif)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink
![A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt-2022-0024/asset/images/medium/figure1.gif)
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy
![2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis | Reumatología Clínica 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis | Reumatología Clínica](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2173574315000878:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIUGeuN4uc6Eu+TxpV8lScsEJf6UngeNSt5Ba+UnO+21KhduOnqJ7SmKot263Wj61fciUr/lB/rPblfIhHocYvFu410CO86iEjpgvmhx47knrQY0shDy6NCWGWBsTCX4LAA9m+OclHehS69OTTiw9q+AaI+TqQERoHPuEHbGAHrQ27Ya8KbhyzRDFgJdGAHLButogUGxxFssyMVhNRd/k3GDa7g9ODhXfXVxfaYWNQhmY=)